- Business
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS) is a China-based biopharmaceutical company that researches, develops, produces, distributes, and sells in vitro diagnostic reagents and instruments, as well as vaccines, primarily targeting infectious diseases such as HIV, hepatitis viruses (A, B, C, D, E), tuberculosis, syphilis, HPV, influenza A/B, and nasopharyngeal cancer. Its core diagnostic products encompass chemiluminescence immunoassay kits, ELISA kits, colloidal gold rapid tests, nucleic acid extraction and detection systems (including WanTag series, MFCS-6, FMNE-08), molecular diagnostics, bioactive materials (over 300 antigens, antibodies, core enzymes via subsidiary Innobiomax), quality control products (over 150 reference materials), and automated analyzers like Wan600, Wan BC2800, WanTLA for chemiluminescence and biochemistry testing with a menu of 220 assays; vaccine portfolio includes the world's first recombinant hepatitis E vaccine (Hecolin®), bivalent HPV vaccine (Cecolin®, WHO prequalified), nine-valent HPV vaccine (launched in China in 2025), and nasal spray COVID-19 vaccine (Pneucolin®), all developed using proprietary E. coli recombinant virus-like particle technology in collaboration with the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD). Founded in 1991 and headquartered at No. 31 Science Park Road, Changping District, Beijing, China, the company operates principally in China with international distribution of diagnostics and vaccines, serving healthcare providers, blood banks, disease control centers, clinical labs, and third-party testing facilities through segments in diagnostics (including core and innovative solutions like intelligent labs, chronic disease management, women's health programs) and vaccines. Recent developments include the 2025 launch of China's first domestically produced nine-valent HPV vaccine, a strategic partnership with Hoyotek Biomedical Co., Ltd. for enhanced biomedical capabilities, completion of share repurchases with partial cancellation announced in October 2025, winning the China Patent Gold Award in June 2025, and participation in global events like Malaysia WHX Labs 2025, alongside ongoing advancements in bioactive materials self-sufficiency (80%) and innovative assays such as Hepatitis E urine tests, IL-6, HIV 4th generation CLIA, and TB-IGRA for population screening.